Ads
related to: dvd for myeloma treatment centers- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Contact a Representative
For Questions and Information
About This Treatment
- Phase 3 Trial
Search results
Results From The WOW.Com Content Network
In 2019, JTCC received approval from the National Cancer Institute (NCI) as a member of the NCI-approved Georgetown Lombardi Comprehensive Cancer Center. [6] The partnership focuses on advancing research and treatment in breast cancer, cancer prevention and control, experimental therapeutics and molecular oncology.
The preferred treatment for those under the age of 65 is high-dose chemotherapy, commonly with bortezomib-based regimens, and lenalidomide–dexamethasone, [106] to be followed by a stem cell transplant. A 2016 study concluded that stem cell transplant is the preferred treatment for multiple myeloma. [107]
It was designed to rapidly accelerate progress made against multiple myeloma by significantly improving the understanding of the biology of the disease. It is spearheaded by the MMRC and in collaboration with the Broad Institute and the Translational Genomics Research Institute (TGen).
The International Myeloma Foundation (IMF) is an American non-profit organization serving patients with myeloma, a cancer of plasma cells in the bone marrow. The IMF also provides support and information for family members, caregivers of myeloma patients, physicians and nurses.
Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [3] It is generally used together with other medications. [3] It is given by injection. [4]
Dana–Farber Cancer Institute (DFCI) is a comprehensive cancer treatment and research center in Boston, Massachusetts.Dana-Farber is the founding member of the Dana-Farber/Harvard Cancer Center, Harvard's Comprehensive Cancer Center designated by the National Cancer Institute, and one of the 15 clinical affiliates and research institutes of Harvard Medical School.
MMRF was founded in 1998 by twin sisters Kathy Giusti and Karen Andrews, following Kathy's diagnosis with multiple myeloma. Giusti, a pharmaceutical company executive and Harvard Business School Alum, wanted to encourage researchers to develop treatments for multiple myeloma by using business models rather than academic models of drug development.
Lenalidomide, sold under the brand name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). [8] For multiple myeloma, it is a first line treatment, and is given with dexamethasone. [8] It is taken by mouth. [8]
Ad
related to: dvd for myeloma treatment centers